Overview

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

Status:
NOT_YET_RECRUITING

Trial end date:
2028-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.

Phase:

PHASE3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

baricitinib